4.7 Article

KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia

Journal

LEUKEMIA
Volume 29, Issue 8, Pages 1656-1667

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2015.107

Keywords

-

Funding

  1. Jubilaumsfonds of the Austrian National Bank [OENB 15480]
  2. Austrian Science Fund [FWF I-1226-B19]
  3. FP7-ERA-NET Grant TRANSCALL
  4. charitable donation of the Kapsch group
  5. Austrian Science Fund (FWF) [I 1226] Funding Source: researchfish
  6. Austrian Science Fund (FWF) [I1226] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

High hyperdiploidy defines the largest genetic entity of childhood acute lymphoblastic leukemia (ALL). Despite its relatively low recurrence risk, this subgroup generates a high proportion of relapses. The cause and origin of these relapses remains obscure. We therefore explored the mutational landscape in high hyperdiploid (HD) ALL with whole-exome (n = 19) and subsequent targeted deep sequencing of 60 genes in 100 relapsing and 51 non-relapsing cases. We identified multiple clones at diagnosis that were primarily defined by a variety of mutations in receptor tyrosine kinase (RTK)/Ras pathway and chromatin-modifying genes. The relapse clones consisted of reappearing as well as new mutations, and overall contained more mutations. Although RTK/Ras pathway mutations were similarly frequent between diagnosis and relapse, both intergenic and intragenic heterogeneity was essentially lost at relapse. CREBBP mutations, however, increased from initially 18-30% at relapse, then commonly co-occurred with KRAS mutations (P < 0.001) and these relapses appeared primarily early (P = 0.012). Our results confirm the exceptional susceptibility of HD ALL to RTK/Ras pathway and CREBBP mutations, but, more importantly, suggest that mutant KRAS and CREBBP might cooperate and equip cells with the necessary capacity to evolve into a relapse-generating clone.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available